Ondansetron PCD Pharma Franchise Company

Cafoli Lifecare is a leading Ondansetron PCD pharma franchise company in India, offering 19 Ondansetron formulations across tablets, injection, oral drops and suspension. All products are manufactured at WHO-GMP certified, DCGI-approved facilities and offered to franchise partners with exclusive district-wise monopoly rights.

What is Ondansetron?

Ondansetron is a selective serotonin 5-HT3 receptor antagonist. Chemotherapy, radiotherapy and surgery trigger the release of serotonin from enterochromaffin cells in the small intestine, which stimulates 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone, initiating the vomiting reflex. By blocking these receptors both peripherally and centrally, Ondansetron prevents and treats nausea and vomiting. It is listed on the WHO Model List of Essential Medicines.

Available Ondansetron Formulations

The Cafoli Lifecare Ondansetron range comprises 19 formulations in the following dosage forms:

• Tablets
• Injection
• Oral Drops
• Suspension

Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Ondansetron price list.

Therapeutic Applications of Ondansetron

Prescribed under medical supervision for:

• Chemotherapy-induced nausea and vomiting (CINV)
• Radiotherapy-induced nausea and vomiting
• Post-operative nausea and vomiting (PONV)
• Nausea and vomiting associated with acute gastroenteritis, including in children (drops and suspension)
• Selected cases of nausea and vomiting in pregnancy, strictly under obstetric supervision

Prescriber specialties: oncologists, anaesthetists, surgeons, emergency physicians, paediatricians, gastroenterologists and consulting physicians. Ondansetron is a prescription-only medicine; the treating doctor should consider QT-interval effects in at-risk patients.

Why Ondansetron is a High-Potential Molecule for Distributors

Ondansetron is unusual in giving a franchise partner two genuinely independent revenue streams from one molecule. The injectable business is institutional and predictable: every oncology day-care unit, operation theatre and casualty department stocks it as standard, orders are consolidated and placed in bulk through hospital purchase, and the guideline-mandated role in chemotherapy and post-operative vomiting makes it effectively non-substitutable. The oral drops and suspension, meanwhile, sell through retail into paediatric gastroenteritis — an extremely high-incidence, monsoon-peaking indication where parents want relief the same day, so stock turns fast. India's rapidly expanding oncology day-care and surgical capacity means the institutional half of this business is structurally growing, not static. A distributor who wins the Ondansetron allotment gains a credible entry point into hospital purchase departments, which are the hardest accounts to open and the most valuable to hold.

Why Choose Cafoli Lifecare

• Monopoly rights — exclusive district-wise marketing rights across all 19 Ondansetron formulations
• WHO-GMP certified manufacturing and DCGI-approved products
• Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
• 1000+ franchise partners across India with an on-time dispatch record
• Transparent net rates and dedicated franchise support

References

1. WHO Model List of Essential Medicines
2. PubChem — Ondansetron compound record
3. PubMed — Ondansetron in chemotherapy-induced nausea and vomiting